A
Aravindhan Veerapandiyan
Associate Professor
faculty
Peds Pediatrics, College of Medicine
20 h-index
129 pubs
1,371 cited
Research Areas
Biography and Research Information
OverviewAI-generated summary
Aravindhan Veerapandiyan's research focuses on genetic and neurological disorders in children, with a particular emphasis on Duchenne muscular dystrophy and spinal muscular atrophy. He has published work on AAV gene therapy for Duchenne muscular dystrophy, including findings from the EMBARK phase 3 randomized trial, and has also investigated the management of adverse events associated with gene therapy for this condition. His work also extends to spinal muscular atrophy, with publications on expanded access programs for risdiplam and best practices for its management.
Beyond these specific conditions, Dr. Veerapandiyan's research interests encompass broader areas of pediatric health. He has explored the implementation of pharmacogenomics testing in a clinical setting and has published on molecular dysregulation in autism spectrum disorder, as well as the role of semaphorin-plexin signaling in X-linked intellectual disability. His research has also touched upon the incidence of PANDAS and PANS in primary care populations.
Dr. Veerapandiyan holds an h-index of 20 and has authored over 124 publications, accumulating 1,321 citations. He collaborates with multiple researchers at the University of Arkansas for Medical Sciences, including Akilandeswari Aravindhan, Murat Gökden, Pritmohinder S. Gill, and Jeffrey Clothier.
Metrics
- h-index: 20
- Publications: 129
- Citations: 1,371
Selected Publications
-
Safety and efficacy of fordadistrogene movaparvovec in ambulatory participants with Duchenne muscular dystrophy (CIFFREO): a phase 3, double-blind, randomised, placebo-controlled study (2026)
-
Consensus recommendations and considerations for the delivery and monitoring of gene therapy in patients with Duchenne muscular dystrophy (2025)
-
Gaps in the Assessment and Care of Neurodevelopmental and Psychiatric Conditions Associated With Dystrophinopathy (2024)
-
Taking ACTION to detect myocarditis related to recombinant gene transfer therapy for Duchenne Muscular Dystrophy; Consensus recommendations for cardiac surveillance (2024)
-
The <scp>BELS</scp> questionnaire: A novel screening tool for neurodevelopmental and psychiatric symptoms in pediatric dystrophinopathy (2024)
-
Charcot‐Marie‐Tooth disease in children (2024)
-
AAV gene therapy for Duchenne muscular dystrophy: the EMBARK phase 3 randomized trial (2024)
-
Editorial: Pediatric autoimmune neuropsychiatric syndrome (2024)
-
Access to novel therapies for Duchenne muscular dystrophy—Insights from expert treating physicians (2024)
-
Revolutionizing neuromuscular disorders rehabilitation: The virtual reality edge (2024)
-
Long-Term Follow-Up Cares and Check Initiative: A Program to Advance Long-Term Follow-Up in Newborns Identified with a Disease through Newborn Screening (2024)
-
Management of Select Adverse Events Following Delandistrogene Moxeparvovec Gene Therapy for Patients With Duchenne Muscular Dystrophy (2024)
-
Estimate of the incidence of PANDAS and PANS in 3 primary care populations (2023)
-
Epilepsy Characteristics in Duchenne and Becker Muscular Dystrophies (2023)
-
Autosomal Recessive Spastic Ataxia of Charlevoix–Saguenay due to Novel Mutations in the <i>SACS</i> Gene (2022)
Grants & Funding
- Clinical Neurobehavioral Screening Tool for Duchenne and Becker Muscular Dystrophy UAMS ACHRI Flow Through Principal Investigator
- No FP attached UAMS ACHRI Flow Through Principal Investigator
Collaboration Network
Top Collaborators
Akilandeswari Aravindhan
University of Arkansas for Medical Sciences
7 shared publications
In database
- Congenital Myasthenic Syndrome due to a Novel Mutation in CHAT Gene
- Epilepsy in hereditary spastic paraplegia associated with NIPA1 gene
- Limb-Girdle Muscular Dystrophy R9 due to a Novel Complex Insertion/Duplication Variant in <i>FKRP</i> Gene
- Exercise Intolerance and Rhabdomyolysis Due to Dystrophinopathy: A Pseudometabolic Presentation
- Infantile-Onset Complex Hereditary Spastic Paraplegia Due to a Novel Mutation in SPAST Gene
Showing 5 of 7 shared publications
Vamshi K. Rao
5 shared publications
- An expanded access program of risdiplam for patients with Type 1 or 2 spinal muscular atrophy
- Palliative care in Duchenne muscular dystrophy: Goals of care discussions and beyond
- RGX-202, an Investigational Gene Therapy for the Treatment of Duchenne Muscular Dystrophy: Interim Clinical Data (S21.005)
- Access to novel therapies for Duchenne muscular dystrophy—Insights from expert treating physicians
- 407P RGX-202, an investigational gene therapy for the treatment of Duchenne muscular dystrophy: interim clinical data
Rachel Schrader
5 shared publications
- Access to novel therapies for Duchenne muscular dystrophy—Insights from expert treating physicians
- 132 Caregivers Perspectives on Multidisciplinary Clinic Visits for Duchenne and Becker Muscular Dystrophy
- Caregivers Perspectives on Multidisciplinary Clinic Visits for Duchenne and Becker Muscular Dystrophy (P5-8.015)
- Healthcare Providers’ Practice and Perception on Discussing Life Expectancy with Duchenne Patients and Caregivers: A Mixed Quantitative/Qualitative Survey (P10-8.008)
- 337P Functional assessments used in routine care for Duchenne muscular dystrophy in the USA: a survey of Certified Duchenne Care Centers
Praveen Kumar Ramani
Arkansas Children's Hospital (US)
4 shared publications
- Epilepsy Characteristics in Duchenne and Becker Muscular Dystrophies
- Child Neurology: <i>KMT2B</i> -Related Dystonia in a Young Child With Worsening Gait Abnormality
- Assessing Sleep Quality in Children with Migraines: Implementation of Electronic Health Record Cue (S4.005)
- Charcot‐Marie‐Tooth disease in children
Crystal M. Proud
Children's Hospital of The King's Daughters (US)
4 shared publications
- AAV gene therapy for Duchenne muscular dystrophy: the EMBARK phase 3 randomized trial
- Spinal Muscular Atrophy Update in Best Practices
- Management of Select Adverse Events Following Delandistrogene Moxeparvovec Gene Therapy for Patients With Duchenne Muscular Dystrophy
- Equitable Access of Delandistrogene Moxeparvovec for Patients With Duchenne Muscular Dystrophy: A Call for Discussion
Ruthwik Duvuru
University of Arkansas for Medical Sciences (US)
4 shared publications
- Acute Liver Injury Following Delandistrogene Moxeparvovec Gene Therapy Requiring Intravenous Immunoglobulin
- Revolutionizing neuromuscular disorders rehabilitation: The virtual reality edge
- Transforming care for spinal muscular atrophy: A critical look at treatment paradigms
- Charcot‐Marie‐Tooth disease in children
Carolina Tesi Rocha
Children's Health Council (US)
4 shared publications
- Access to novel therapies for Duchenne muscular dystrophy—Insights from expert treating physicians
- 407P RGX-202, an investigational gene therapy for the treatment of Duchenne muscular dystrophy: interim clinical data
- Del-Zota Produced Statistically Significant Increases in Exon Skipping and Dystrophin Levels in EXPLORE44: A Phase 1/2 Study in Patients with DMD44
- 674PDelpacibart zotadirsen (del-zota) increased dystrophin and improved muscle integrity markers regardless of ambulatory status in individuals with DMD44
Murat Gökden
University of Arkansas for Medical Sciences
3 shared publications
In database
- Mitochondrial Ultrastructural Defects in NDUFS3-Related Disorder
- Limb-Girdle Muscular Dystrophy R9 due to a Novel Complex Insertion/Duplication Variant in <i>FKRP</i> Gene
- Miyoshi Muscular Dystrophy Due to Novel Splice Site Variants in <i>DYSF</i> Gene
H. Phan
Rare Disease Therapeutics (United States) (US)
3 shared publications
- An expanded access program of risdiplam for patients with Type 1 or 2 spinal muscular atrophy
- Del-Zota Produced Statistically Significant Increases in Exon Skipping and Dystrophin Levels in EXPLORE44: A Phase 1/2 Study in Patients with DMD44
- 674PDelpacibart zotadirsen (del-zota) increased dystrophin and improved muscle integrity markers regardless of ambulatory status in individuals with DMD44
Emma Ciafaloni
University of Rochester Medical Center (US)
3 shared publications
- AAV gene therapy for Duchenne muscular dystrophy: the EMBARK phase 3 randomized trial
- Epilepsy Characteristics in Duchenne and Becker Muscular Dystrophies
- Long-Term Follow-Up Cares and Check Initiative: A Program to Advance Long-Term Follow-Up in Newborns Identified with a Disease through Newborn Screening
Russell J. Butterfield
University of Utah (US)
3 shared publications
- Management of Select Adverse Events Following Delandistrogene Moxeparvovec Gene Therapy for Patients With Duchenne Muscular Dystrophy
- Consensus recommendations and considerations for the delivery and monitoring of gene therapy in patients with Duchenne muscular dystrophy
- Long-Term Follow-Up Cares and Check Initiative: A Program to Advance Long-Term Follow-Up in Newborns Identified with a Disease through Newborn Screening
Craig M. McDonald
University of California, Davis (US)
3 shared publications
- AAV gene therapy for Duchenne muscular dystrophy: the EMBARK phase 3 randomized trial
- Access to novel therapies for Duchenne muscular dystrophy—Insights from expert treating physicians
- Consensus recommendations and considerations for the delivery and monitoring of gene therapy in patients with Duchenne muscular dystrophy
Jonathan H. Soslow
Monroe Carell Jr. Children's Hospital (US)
3 shared publications
- Acute Liver Injury Following Delandistrogene Moxeparvovec Gene Therapy Requiring Intravenous Immunoglobulin
- Access to novel therapies for Duchenne muscular dystrophy—Insights from expert treating physicians
- Taking ACTION to detect myocarditis related to recombinant gene transfer therapy for Duchenne Muscular Dystrophy; Consensus recommendations for cardiac surveillance
W. Bryan Burnette
Vanderbilt University Medical Center (US)
3 shared publications
- Spinal Muscular Atrophy Update in Best Practices
- Acute Liver Injury Following Delandistrogene Moxeparvovec Gene Therapy Requiring Intravenous Immunoglobulin
- Access to novel therapies for Duchenne muscular dystrophy—Insights from expert treating physicians
Thirumalaivasan Dhasakeerthi
University of Tennessee Health Science Center (US)
2 shared publications
- Congenital Myasthenic Syndrome due to a Novel Mutation in CHAT Gene
- A rare neuro-ophthalmological phenomenon: Marcus Gunn jaw winking ptosis
Similar Researchers
Based on overlapping research topics
Alexandrea Wadley
University of Arkansas for Medical Sciences
Metabolism and Genetic Disorders
Neurological disorders and treatments
Child and Adolescent Health
Eniya Beemarajan
University of Arkansas for Medical Sciences
Metabolism and Genetic Disorders
Neurological disorders and treatments
Child and Adolescent Health
Mack B. Stokes
University of Arkansas for Medical Sciences
Metabolism and Genetic Disorders
Child and Adolescent Health
Genomics and Rare Diseases
Aixa Gonzalez Garcia
University of Arkansas for Medical Sciences
Metabolism and Genetic Disorders
Neurological disorders and treatments
Child and Adolescent Health
Thomas Andrew Burrow
University of Arkansas for Medical Sciences
Metabolism and Genetic Disorders
Neurological disorders and treatments
Child and Adolescent Health
Michele Yang
University of Arkansas for Medical Sciences
Metabolism and Genetic Disorders
Neurological disorders and treatments
Child and Adolescent Health